Interactions of Human Monoclonal and Polyclonal Antiphospholipid Antibodies With Serine Proteases Involved in Hemostasis

Anastasia Lambrianides, Tabitha Turner-Stokes, Charis Pericleous, Jasmine Ehsanullah, Eva Papadimitraki, Katie Poulton, Yiannis Ioannou, Andrew Lawrie, Ian Mackie, Pojen Chen, David Latchman, David Isenberg, Anisur Rahman, and Ian Giles

Objective. To characterize the interaction between procoagulant and/or anticoagulant serine proteases and human monoclonal IgG antiphospholipid antibodies (aPL) and polyclonal IgG derived from patients with the antiphospholipid syndrome (APS).

Methods. Five human monoclonal IgG with small differences in their sequences were tested for binding to protein C, activated protein C, plasmin, factor VIIa (FVIIa), FIX, FIXa, and FXII. Serum levels of antithrombin and anti–activated protein C were compared in 32 patients with APS, 29 patients with systemic lupus erythematosus (SLE), and 22 healthy controls. Purified polyclonal IgG derived from APS patients with elevated levels of serum antithrombin antibodies was also tested for its functional effects on thrombin and antithrombin activity.

Results. Studies of monoclonal antibodies showed that sequence changes in human aPL are important in determining their ability to bind procoagulant and anticoagulant/fibrinolytic serine proteases. Mean IgG antithrombin levels were significantly elevated in patients with APS and in SLE patients with aPL but no APS (SLE/aPL+) compared to healthy controls, but anti–activated protein C levels were not increased in these patients. Moreover, IgG purified from patients with APS displayed higher avidity for thrombin and significantly inhibited antithrombin inactivation of thrombin compared with IgG from SLE/aPL+ patients.

Conclusion. High-avidity antithrombin antibodies, which prevent antithrombin inactivation of thrombin, distinguish patients with APS from SLE/aPL+ patients, and thus may contribute to the pathogenesis of vascular thrombosis in APS.

Antiphospholipid antibodies (aPL) cause vascular thrombosis and/or pregnancy morbidity in the antiphospholipid syndrome (APS) (1). These clinical manifestations are triggered by the interaction of pathogenic aPL with various target cells, including monocytes, endothelial cells, and trophoblast cells, leading to the recruitment of cell surface receptors and subsequent perturbation of intracellular signaling pathways (2). These pathogenic aPL are generally IgG type (3,4) and target a variety of antigens, including negative phospholipid, phospholipid binding proteins (particularly β2-glycoprotein I [β2GPI] and prothrombin), as well as other factors related to hemostasis, such as thrombin, protein C, activated protein C, protein S, plasmin, plasminogen, and tissue-type plasminogen activator (tPA) (5–13). In contrast, nonpathogenic aPL (found in 2–5% of healthy adults who lack features of the APS [14]) mostly bind directly to phospholipid (15).

Thrombin, activated protein C, plasmin, and tPA, as well as activated factor VIIa (FVIIa), FIXa, FXa, and...
FXIIa, belong to the trypsin-like serine protease family of enzymes and are involved in the tight regulation of hemostasis (16). In previous studies, sera from between 13% and 54% of patients with the APS have been found to bind various different serine proteases (5,8,13). Furthermore, a panel of human monoclonal aPL produced from hybridomas displayed cross-reactivity with serine protease, binding to thrombin, activated protein C, plasmin, tPA, FXa, and FXa (6–8,17,18). Overall, these serine proteases share ~50% amino acid sequence similarity in their enzymatic domains but have greater homology at their catalytic sites. Given that several human monoclonal aPL have been found to inhibit the inactivation of procoagulant serine proteases and functional activities of anticoagulant/fibrinolytic serine proteases (7,8,13,19), it has been suggested that some aPL may recognize the catalytic domain of serine proteases, leading to dysregulation of hemostasis and vascular thrombosis in the APS.

To explore the interaction of aPL with target antigens in promoting thrombus formation, we have been studying a panel of recombinant human monoclonal IgG aPL, which differ from one another at points in their sequence precisely engineered by us. Studying this panel of IgG molecules has allowed us to investigate correlations between their sequences, binding, and biologic properties (20–23). These human monoclonal IgG aPL were all based on the human monoclonal IgG aPL IS4 (derived from a patient with APS), which binds $\beta_2$GPI (24) and thrombin (8) and is thrombogenic in mice (25). Previously, we found that alterations in the pattern of somatic mutations in both the $V_H$ and $V_L$ regions of IS4 determined its ability to bind antigens relevant in the pathogenesis of the APS and to promote murine thrombogenesis (20–23). Interestingly, the in vivo thrombogenic effects of these monoclonal antibodies (mAb) were most closely predicted by their ability to bind thrombin, rather than phospholipid or $\beta_2$GPI. Furthermore, mAb binding to thrombin followed a different pattern compared to the pattern observed with mAb binding to its zymogen prothrombin (21).

Therefore, in the current study we used the same panel of mAb to examine whether binding to other serine proteases also parallels thrombogenicity in the mouse model, and whether the difference between binding to prothrombin and binding to thrombin is also seen with other zymogen/enzyme pairs, i.e., FIX and FIXa, or protein C and activated protein C. To assess the relevance of our findings obtained using monoclonal IgG aPL to polyclonal aPL found in vivo, we then tested serum samples and purified IgG samples from APS patients, systemic lupus erythematosus (SLE) patients without APS (subclassified according to positivity or negativity for aPL), and healthy controls. We investigated whether samples from those groups differed in the nature and avidity of their binding to serine proteases and ability to alter the functional activity of serine proteases.

**PATIENTS AND METHODS**

**Human monoclonal IgG antibodies.** Production of the antibodies (IS4VH/IS4VL, IS4VH/B3VL, IS4VH/UK4VL, IS4VHI&ii/IS4VL, and IS4VHI&ii/B3VL) has been well described (21,23,26,27). Variant forms of IgG were produced by site-directed mutagenesis in IS4VHCDR3 and/or by replacing IS4VL with similar $V_L$ chains from an antinucleosome mAb (B3 [28]) or a $\beta_2$GPI-independent aPL (UK4 [29]). These $V_L$ chains were all derived from the germline $V_{\lambda}$ gene (2a2), sharing at least 93% sequence homology and differing solely in their pattern of somatic mutation (23). IS4VHI&ii differs from IS4VH in 2 arginine-to-serine mutations at positions 96 and 97. An irrelevant nonbinding monoclonal IgG antibody was produced in an identical manner and used as a negative control. Large-scale production and purification of IgG was performed by an outside company (Harlan). The concentration of IgG was confirmed by both total IgG enzyme-linked immunosorbent assay (ELISA) (23) and spectrophotometry.

**Patients and healthy controls.** Serum samples for this study were obtained from 83 individuals (patients under our care at University College London Hospital and healthy controls) (Table 1). All subjects had provided written informed consent. Of 32 patients fulfilling the revised classification criteria for APS (1), 14 also had SLE fulfilling the American College of Rheumatology (ACR) classification criteria (30) and 18 had primary APS. Consistent with findings from other cohort studies (31,32) the APS-related clinical and serologic features in our primary APS and SLE/APS groups were similar, and these patients were therefore combined into one group called APS. As an autoimmune disease control group we obtained samples from 29 patients who had SLE (fulfilling the ACR criteria) but did not have APS. Thirteen were aPL positive (SLE/aPL+) and 16 were aPL negative (SLE/aPL−). The healthy control group consisted of 22 individuals. To ensure that any residual thrombin present in serum was rapidly inhibited by antithrombin or $\alpha_2$-macroglobulin and/or absorbed by fibrin, all patient/control blood samples were left to clot for 2 hours before centrifugation and collection of serum. Results of experiments to confirm that there was no residual thrombin activity in serum at dilutions used in subsequent ELISAs are available at http://discovery.ucl.ac.uk/1316886/.

**Purification and immunologic characterization of IgG.** All IgG was purified by protein G–Sepharose affinity chromatography (GE Healthcare Lifesciences). The concentration of purified IgG was determined using a Nanodrop ND-1000 Spectrophotometer (LabTech International). Anticardiolipin antibody (aCL) and IgG anti-$\beta_2$GPI titers were measured in all serum samples as previously described (21), using international calibrators (Louisville APL Diagnostics) and the IgG Sapporo standard, HCAL (Centers for Disease Control and Preven-
Table 1. Clinical and laboratory features of the subjects studied

|                             | APS (n = 22) | SLE/aPL+ (n = 13) | SLE/aPL− (n = 16) | Healthy controls (n = 22) |
|-----------------------------|-------------|------------------|------------------|--------------------------|
| Age, mean years             | 49.59       | 41.69            | 39.44            | 35.32                    |
| Sex, male/female            | 0/32        | 0/13             | 2/14             | 9/13                     |
| Vascular thrombosis         | DVT (n = 9), PE (n = 9), CVA (n = 9), TIA (n = 5) | None            | DVT (n = 1), PE (n = 1) | None                     |
| Pregnancy morbidity         | RM (n = 31), FD (n = 17) | None            | None             | None                     |
| Other ARD                   | SLE (n = 14) | Aspirin (n = 9), warfarin (n = 12), steroids (n = 5), immunosuppressive drugs (n = 1) | None             | None                     |
| Treatment                   |             | Aspirin (n = 9), warfarin (n = 12), steroids (n = 9), immunosuppressive drugs (n = 8) | Aspirin (n = 4), steroids (n = 9) | None                     |
| aCL, mean GPL units         | 55.28       | 8.61             | 13.36            | 11.82                    |
| Anti-β2 GPI, mean AU        | 22.34       | 19               | 0.25             | 0.26                     |
| LAC positive                | 23          | 9                | 0                | 0                        |

* Except where indicated otherwise, values are the number of patients. APS = antiphospholipid syndrome; SLE/aPL+ = antiphospholipid antibody–positive systemic lupus erythematosus; SLE/aPL− = antiphospholipid antibody–negative systemic lupus erythematosus; DVT = deep vein thrombosis; PE = pulmonary embolism; CVA = cerebrovascular accident; TIA = transient ischemic attack; RM = recurrent miscarriages (≥3 first-trimester miscarriages); FD = fetal death; ARD = autoimmune rheumatic disease; aCL = anticardiolipin antibody; GPL = IgG phospholipid; anti-β2GPI = anti-β2-glycoprotein I; AU = arbitrary units; LAC = lupus anticoagulant

**Antithrombin antibodies.** Antithrombin antibodies were detected as described previously (8,20).

**Protein C and protein C ACTIVATED.** Anti–factor VIIa ELISA. IgG anti–factor VIIa antibodies were detected using the method described by Yang et al (13). The test half of a high-binding Costar plate was coated with 5 μg/ml human plasmolin (Haematologic Technologies) in phosphate buffered saline (PBS); PBS alone was used on the control half. Plates were incubated overnight at 4°C and blocked with PBS/0.05% gelatin for 1 hour at room temperature. Monoclonal IgG (100 μg/ml) in PBS/0.1% gelatin was incubated for 1.5 hours at room temperature. Bound IgG was detected by addition of anti–human IgG Fc–specific alkaline phosphatase conjugate in PBS/0.1% gelatin for 1 hour followed by addition of substrate, and absorbance was read at 405 nm.

**Anti–factor VIIIa ELISA.** IgG anti–factor VIIIa antibodies were detected according to the method described by Bidot et al (33). MaxiSorp plates were coated with 1.5 μg/ml recombinant human FVIIIa (Novo Nordisk) in PBS on the test half and PBS alone on the control half. Plates were incubated overnight at 4°C and then blocked with 200 μl PBS/0.1% Tween/2% bovine serum albumin (BSA) for 2 hours at room temperature. Monoclonal IgG (100 μg/ml) in PBS/1% BSA was incubated at room temperature for 1 hour. Bound IgG was detected by addition of anti–human IgG Fc–specific alkaline phosphatase conjugate in PBS/1% BSA for 1 hour followed by addition of substrate, and absorbance was read at 405 nm.

**Anti–factor XII ELISA.** To detect IgG anti–factor XII antibodies, a modification of the method of Jones et al (34) was used. MaxiSorp plates were coated with 5 μg/ml FXII (Haematologic Technologies) in carbonate–bicarbonate buffer on the test half of the plate and carbonate–bicarbonate buffer alone on the control half. Plates were then incubated for 1 hour at room temperature and blocked with Tris buffered saline (TBS)/2% BSA for 1 hour at room temperature. Monoclonal IgG (100 μg/ml) in TBS/1% BSA was incubated at room temperature for 1 hour and bound IgG detected by the addition of anti–human IgG Fc–specific alkaline phosphatase for 1 hour followed by addition of substrate, and absorbance was read at 405 nm.

**Anti–protein C and anti–activated protein C ELISA.** Anti–protein C and anti–activated protein C binding was measured as described by Hwang et al (19). The test half of a high-binding Costar plate was coated with 5 μg/ml protein C or activated protein C (Haematologic Technologies) in TBS/2.5 mM CaCl2; TBS/2.5 mM CaCl2 alone was used on the control half. The plates were washed with TBS/2.5 mM CaCl2 and blocked using TBS/2.5 mM CaCl2/0.3% gelatin. Monoclonal IgG was diluted in TBS/2.5 mM CaCl2/0.1% gelatin and incubated for 1 hour at room temperature. For testing of serum the assay was modified, with protein C/activated protein C used at 10 μg/ml, serum diluted 1:25 in TBS/2.5 mM CaCl2/0.1% gelatin, and incubation carried out for 1.5 hours.

**Anti–protein IX and anti–factor IXa ELISA.** Anti–FIX and anti–FIXa antibodies were detected using the method of Yang et al (17). The test half of a high-binding Costar plate was coated with 5 μg/ml FIX or FIXa (Haematologic Technologies) in TBS; TBS alone was used on the control half. Plates were incubated overnight at 4°C and blocked with 100 μl TBS/0.3% gelatin for 1 hour at room temperature. Monoclonal IgG (100 μg/ml) in TBS/0.1% gelatin was incubated at room temperature for 1.5 hours. Bound IgG was detected by addition of anti–human IgG Fc–specific alkaline phosphatase conjugate in TBS/0.1% gelatin for 1 hour followed by addition of substrate, and absorbance was read at 405 nm.

**Achaetocropic ELISA for determination of avidity of antithrombin antibodies.** Achaetocropic ELISA for antithrombin antibody avidity was adapted from that described by Cucnik et al (35), whose achaetocropic ELISA was established using NaCl to measure the avidity of IgG–β2GPI interactions in patients with APS. Briefly, high-binding Costar plates were coated with 10 μg/ml human α-thrombin, incubated overnight, and blocked as described above. IgG was purified from the
ANTIPHOSPHOLIPID ANTIBODIES AND SERINE PROTEASES

This page contains a table summarizing binding and functional characteristics of 5 heavy/light chain combinations. The table includes columns for heavy chain/light chain, thrombin, plasmin, activated protein C, activated FVIIa, FIX, FIXa, FXII, and inhibition of thrombin/activated protein C/antithrombin activity. The table uses symbols to indicate binding strength, with '++' representing the strongest binding.

**RESULTS**

Binding properties and functional effects of monoclonal IgG on serine proteases. We examined binding of the monoclonal IgG to 4 procoagulant (FVIIa, FIXa, FIX, and FXII) and 3 anticoagulant/fibrinolytic (plasmin, activated protein C, and protein C) serine protease/zymogens. None of these serine proteases showed the same pattern of binding to these 5 mAbs, as previously seen with thrombin (20). Only 2 mAbs, one of which had strong antithrombin binding (IS4VHii/B3VL) and the other of which had no antithrombin binding (IS4VH/B3VL), displayed weak binding to FVIIa, which failed to reach statistical significance compared with control IgG (Table 2 and Figure 1A). The other 3 IS4 variants, including native IS4VH/IS4VL, exhibited negligible anti-FVIIa binding. In contrast, all of the IS4 variants displayed moderate binding to FIXa and FXII (Table 2 and Figure 1A). Binding of IS4VHii/B3VL to FIXa and binding of IS4VH/IS4VL to FXII were significantly increased (P < 0.05) compared with control IgG. Only 2 of the 5 IS4

---

Table 2. Summary of binding and functional characteristics of the 5 heavy/light chain combinations

| Heavy chain/light chain | CL | Thrombin | Plasmin | Protein C | Activated protein C | FVIIa | FIX | FIXa | FXII |
|-------------------------|----|----------|---------|-----------|---------------------|-------|-----|------|------|
| IS4VH/IS4VL             | +  | ++       | –       | –         | –                   | ++    | +   | ++   | –    |
| IS4VHii/IS4VL           | –  | +        | –       | +         | –                   | –     | –   | +    | +    |
| IS4VH/B3VL              | +  | +        | –       | –         | –                   | +     | –   | +    | +    |
| IS4VHii/B3VL            | ++ | +        | +       | +         | +                   | +     | +   | +    | +    |
| IS4VH/UK4VL             | +  | +        | –       | –         | –                   | –     | +   | ++   | –    |

* Binding of purified IgG to cardiolipin (CL), thrombin, plasmin, protein C, activated protein C, factor VIIa (FVIIa), FIX, FIXa, and FXII and ability to inhibit thrombin, activated protein C, and antithrombin activity are shown. The identity of native heavy and light chains is clearly indicated. IS4VHii contains 2 Arg-to-Ser replacements at positions 96 and 97. Each VH/VL combination was tested at 100 μg/ml in triplicate, and the degree of binding was defined from the mean absorbance, as follows: – = optical density (OD) <0.1; + = OD 0.1–0.4; ++ = OD >0.4–0.8; +++ = OD >0.8–1.2; ++++ = OD >1.2.
variants (IS4VHi&ii/B3VL and IS4VH/UK4VL) showed moderate binding to FIX (Table 2 and Figure 1A), with the increase being significant only for IS4VHi&ii/B3VL (\(P < 0.01\)). Only 1 heavy/light chain combination (IS4VHi&ii/B3VL) displayed any evidence of binding to the fibrinolytic serine protease plasmin (\(P < 0.05\) compared with control IgG), the anticoagulant serine protease activated protein C, and the zymogen protein C (Table 2 and Figure 1B).

We compared binding of monoclonal IgG to 2 zymogen/serine protease pairs. The zymogen protein C and its serine protease activated protein C exhibited very similar patterns of binding (Figure 1B). Only IS4VHi&ii/B3VL displayed greater binding to protein C than to activated protein C.

**Detection of antithrombin and anti–activated protein C binding in the serum of patients with APS.** We then examined IgG antithrombin and anti–activated protein C antibodies in patients with APS, patients with SLE, and healthy controls. Figure 2A shows that mean IgG antithrombin levels were significantly increased in the 2 groups of patients who were positive for serum aPL (24.1 AU in the APS group and 31.3 AU in the SLE/aPL+ group, compared with 14.6 AU in the SLE/aPL− group and 13.6 AU in the healthy controls). There were statistically significant differences between the APS group and the healthy controls (\(P < 0.05\)), between the SLE/aPL+ group and the healthy controls (\(P < 0.01\)), and between the SLE/aPL+ group and the SLE/aPL− group (\(P < 0.01\)). The upper limit of normal in this assay was defined as 3 SD above the mean in the healthy control group, i.e., 30.7 AU. Using this cutoff, antithrombin antibodies were present in 10 of the patients in the APS group and 5 of the patients in the SLE/aPL+ group (38.5%), compared to only 1 patient in the SLE/aPL− group (6%).

In contrast, there were no significant differences in IgG anti–activated protein C levels between any of the groups studied (Figure 2B). Anti–activated protein C antibodies were present (i.e., levels more than 3 SD above the mean in healthy controls) in 5 of the APS patients and 2 (15.4%) of the SLE/aPL+ patients. Furthermore, in the 45 subjects who were aPL positive (32 APS and 13 SLE/aPL+), antithrombin titers were not correlated with titers of aCL (\(r = 0.018, P = 0.92\)), anti-β2GPI (\(r = 0.15, P = 0.31\)), or anti–activated protein C (\(r = 0.27, P = 0.31\)).

**Avidity of antithrombin antibodies.** As described above, 16 patients were found to be positive for antithrombin antibodies (10 with APS, 5 with aPL+ SLE, and 1 with aPL− SLE). To investigate whether there was any difference in the avidity of these antibodies for
thrombin between the APS and the SLE/aPL+ groups, we introduced chaotropic conditions to the thrombin ELISA. Interestingly, as the concentration of NaCl was increased above 1M, the mean residual binding of polyclonal IgG to thrombin was higher in samples from patients with APS compared to patients with SLE and aPL but without APS (Figure 3A). The difference between the 2 groups increased as the concentration of NaCl increased (Figures 3B and C), reaching statistical significance at 2M NaCl (mean residual binding 20.0% in the APS group versus 10.9% in the SLE group; \( P < 0.05 \)) (Figure 3C).

Functional properties of antithrombin antibodies. To investigate the functional significance of the thrombin-reactive IgG, we examined the effect of IgG purified from the serum of 9 of the 10 antithrombin antibody–positive APS patients on the inhibition of thrombin by antithrombin. We compared the results to those obtained using IgG purified from the sera of the 6 antithrombin antibody–positive patients with SLE but no APS and 7 healthy controls (Figures 4A and B). IgG from patients with APS significantly reduced the inactivation of thrombin by antithrombin compared to IgG isolated from patients with SLE at both 1 minute (\( P < 0.01 \)) (Figure 4B) and 2 minutes (\( P < 0.05 \)) (data not shown), but there was no significant difference between the results obtained using IgG from APS patients and healthy controls. No statistically significant differences were found at 4 minutes; beyond this time point, the linear rate of absorbance plateaus and it is difficult to accurately measure degree of inhibition by antithrombin. When this assay was carried out in the absence of antithrombin, i.e., to determine whether there was any direct effect of the IgG on the action of thrombin, none of the IgG tested had any effect on the activity of thrombin alone (data not shown).

**DISCUSSION**

In our previous studies using a panel of 5 human monoclonal IgG aPL (20), only 2 (IS4VH/IS4VL and IS4VHi\&ii/B3VL) showed an association between thrombin binding in vitro and ability to promote murine thrombosis in vivo. In the present investigation we demonstrated that this finding is not a class effect common to the 4 other serine proteases and 3 zymogens tested, since binding to these antigens did not distinguish pathogenic (IS4VH/IS4VL and IS4VHi\&ii/B3VL) from
nonpathogenic (IS4VHi\&ii/IS4VL, IS4VH/B3VL, and IS4VH/UK4VL) mAb in the way previously demonstrated for antithrombin binding. Although the combination IS4VHi\&ii/B3VL is able to bind all 5 active serine proteases tested so far (thrombin, plasmin, FIXa, FVIIa, and activated protein C), it also binds well to the zymogens FIX, FXII, and protein C, in which the serine protease catalytic site is not exposed. The other throm-
bogenic combination, IS4VH/IS4VL, also does not bind serine proteases better than zymogens; it binds the serine proteases thrombin and FIXa, but not activated protein C, plasmin, or FVIIa. Hence, only binding to thrombin by a large panel of well-characterized human-derived mAb predicted their pathogenicity in mice. Therefore, we characterized the interaction between human-derived polyclonal antibodies from the sera of patients (APS and control patients) and thrombin, to elucidate the relevance of these findings in disease.

Several different groups have identified anti–serine protease antibodies in patients with APS (5,7,8,13,17,18,33,37), although the clinical significance of these findings has yet to be established. Since some serine proteases exert procoagulant effects whereas others exert anticoagulant effects, it may prove difficult to identify the effects of anti–serine protease antibodies on hemostasis in vivo. Given our demonstration, in experiments using human monoclonal IgG aPL, of the importance of binding to thrombin, we investigated the nature, avidity, and functional effects of IgG antithrombin antibodies in patients with APS. We found antithrombin antibody levels to be elevated above the cutoff in 31.3% of our APS patient cohort, with no significant correlation between antithrombin antibody levels and aCL or anti-β2GPI antibody levels. Direct binding of β2GPI to thrombin was recently demonstrated (38), and this binding was subsequently shown to protect against thrombin inactivation by heparin cofactor II, with the procoagulant effect potentiated by anti-β2GPI antibodies (39). Our present findings, however, demonstrate that antithrombin binding is not simply a surrogate marker for anti-β2GPI binding and that these antibodies are distinct from other aPL. IgG from patients with APS did not inhibit thrombin activity, although these IgG reduced the antithrombin inhibition of thrombin. This suggests that the IgG from patients with APS bind to the exosite or heparin binding site on thrombin, rather than the catalytic site.

The antithrombin antibodies were not specific to APS: 38.5% of the patients with SLE who were positive for aPL but lacked clinical features of APS were also found to have significantly elevated levels of antithrombin antibodies. Although based on samples from a relatively small number of patients, our results (Figures 3 and 4) demonstrate that there are differences between the antithrombin antibodies found in patients with APS and those found in patients with SLE but without APS. The antithrombin antibodies from patients with APS have a higher avidity for thrombin than those from patients with SLE without APS, and the antithrombin-mediated inactivation of thrombin by purified IgG from patients with APS was significantly reduced at time points up to 2 minutes compared with that by purified IgG from patients with SLE.

These findings are relevant to the pathogenesis of APS, since high-avidity antithrombin antibodies, which prevent thrombin inactivation, are more likely to promote vascular thrombosis than are low-avidity antithrombin antibodies, which lack this function. Indeed, previous testing of a panel of hybridoma-derived monoclonal aPL showed that an aPL (named CL24) with the greatest avidity for binding to thrombin exerted the strongest inhibition of antithrombin activity (8) and was thrombogenic in mice (25). These results mirror those of other groups who have demonstrated that high-avidity serum anti-β2GPI antibodies are more closely associated with thrombosis than are low-avidity serum anti-β2GPI antibodies in patients with APS (35). Consequently, these differences in binding avidity may contribute to the phenotypic differences between APS patients and SLE patients with respect to their predisposition to thrombus formation.

Interestingly, although anti–activated protein C antibodies have been described in patients with the APS, we did not find significantly increased levels of these antibodies in our cohort of APS patients compared to healthy controls (Figure 2B). Hence, despite the fact that the catalytic sites of activated protein C and thrombin share ~50% amino acid sequence homology, antithrombin antibodies in our patient cohort do not appear to cross-react with activated protein C. Therefore, the results of our experiments on patient serum are consistent with the impression derived from the mAb experiments, i.e., that anti–serine protease antibodies in patients with APS do not interact with epitopes in the shared catalytic sites of serine protease, and that antibodies against the procoagulant serine protease thrombin, rather than the anticoagulant serine protease activated protein C, are associated with promotion of thrombosis.

The end point of coagulation, however, is a series of interactions between inhibitors and procoagulants, leading to thrombin generation. To more thoroughly understand the impact of aPL on the net effect of the coagulation cascade leading to thrombin generation, it is necessary to ascertain their effects in a global coagulation assay measuring endogenous thrombin potential. To begin to address this we have performed preliminary experiments examining the effects of selected IgG on thrombin generation, assessed based on endogenous thrombin potential, under various experimental condi-
tions. We compared 2 IgG samples with high-avidity thrombin binding (from patients with APS) and 2 samples with low-avidity thrombin binding (from patients with SLE) and found no appreciable difference in the effect of these IgG samples on endogenous thrombin potential (data available at http://discovery.ucl.ac.uk/1316886/). Further experiments using activity assays are now needed to investigate the effect of these antibodies on different functions of thrombin, in order to better understand their role in the pathogenesis of the APS.

Our study has some limitations. For pragmatic reasons we were able to analyze binding of serum to only 2 serine proteases: thrombin and activated protein C. It remains possible that antibodies to other procoagulant or anticoagulant serine proteases were important in the pathogenesis of APS in our patients. The chaotropic method that we used to assess avidity of binding yielded interesting results, but antigen–antibody binding under high-salt conditions may also be affected by changes in hydrophobicity of the interaction. In future studies it would be useful to add other methods for measuring avidity, such as surface plasmon resonance.

In conclusion, we have demonstrated that sequence changes in both the V_H and the V_L regions of human aPL alter their ability to bind procoagulant and anticoagulant/fibrinolytic serine proteases but have no effect on in vitro serine protease activity. Furthermore, we have shown that antithrombin antibodies in patients with APS have high avidity and prevent antithrombin inactivation of thrombin compared to those in aPL-positive patients with SLE but without APS. These properties may contribute to the pathogenesis of vascular thrombosis in APS.

ACKNOWLEDGMENTS

We are indebted to Drs. Siobhan O’Brien and Alison Levy for their help and advice on the assembly of constructs for expression.

AUTHOR CONTRIBUTIONS

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Dr. Lambrianides had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study conception and design. Lambrianides, Pericleous, Ioannou, Lawrie, Mackie, Latchman, Isenberg, Rahman, Giles.

Acquisition of data. Lambrianides, Turner-Stokes, Pericleous, Ehsanullah, Papadimitraki, Poulton, Lawrie.

Analysis and interpretation of data. Lambrianides, Turner-Stokes, Pericleous, Papadimitraki, Ioannou, Lawrie, Chen, Latchman, Rahman, Giles.

REFERENCES

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295–306.

2. Giannakopoulos B, Passam F, Rahgozari S, Krilis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 2007;109:422–30.

3. Alarcon-Segovia D, Deleze M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L, Cabiedes J, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 300 consecutive patients. Medicine (Baltimore) 1989;68:353–65.

4. Lynch A, Marlar R, Murphy J, Davila G, Santos M, Rutledge J, et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome: a prospective study. Ann Intern Med 1994;120:470–5.

5. Cugno M, Cabibbe M, Galli M, Meroni PL, Caccia S, Russo R, et al. Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients. Blood 2004;103:2121–6.

6. Lin WS, Chen PC, Yang CD, Cho E, Hahn BH, Grossman J, et al. Some antiphospholipid antibodies recognize conformational epitopes shared by β_2-glycoprotein I and the homologous catalytic domains of several serine proteases. Arthritis Rheum 2007;56:1638–47.

7. Lu CS, Horizon AA, Hwang KK, FitzGerald J, Lin WS, Hahn BH, et al. Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome. Arthritis Rheum 2005;52:4018–27.

8. Hwang KK, Grossman JM, Visvanathan S, Chukwuocha RU, Woods VL Jr, Le DT, et al. Identification of anti-thrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin. J Immunol 2001;167:7192–8.

9. Oosting JD, Derksen RH, Bobbink IW, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 1993;81:2618–25.

10. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990;336:177–8.

11. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544–7.

12. McNeil HP, Simpson RJ, Chesterton CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β_2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990;87:4120–4.

13. Yang CD, Hwang KK, Yan W, Gallagher K, FitzGerald J, Grossman JM, et al. Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin. J Immunol 2004;172:5765–73.

14. Greaves M, Cohen H, MacHin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000;109:704–15.

15. Loizou S, Mackworth-Young CG, Cofiner C, Walport MJ. Heterogeneity of binding reactivity to different phospholipids of antibodies from patients with systemic lupus erythematosus (SLE) and with syphilis. Clin Exp Immunol 1990;80:171–6.

16. Walsh PN, Ahmad SS. Proteases in blood clotting. Essays Biochem 2002;38:95–111.

17. Yang YH, Chien D, Wu M, FitzGerald J, Grossman JM, Hahn BH, et al. Novel autoantibodies against the activated coagulation
factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin. J Immunol 2009;182:1674–80.

18. Yang YH, Hwang KK, FitzGerald J, Grossman JM, Taylor M, Hahn BH, et al. Antibodies against the activated coagulation factor X (FXa) in the antiphospholipid syndrome that interfere with the FXa inactivation by antithrombin. J Immunol 2006;177:8219–25.

19. Hwang KK, Yang CD, Yan W, Grossman JM, Hahn BH, Chen PP. A thrombin–cross-reactive anticardiolipin antibody binds to and inhibits the anticoagulant function of activated protein C. Arthritis Rheum 2003;48:1622–30.

20. Giles I, Pericleous C, Liu X, Ehsanullah J, Clarke L, Brogan P, et al. Thrombin binding predicts the effects of sequence changes in a human monoclonal antiphospholipid antibody on its in vivo biological actions. J Immunol 2009;182:4836–43.

21. Giles I, Lambrianides N, Pattini N, Faulkes D, Latchman D, Chen P, et al. Arginine residues are important in determining the binding of human monoclonal antiphospholipid antibodies to clinically relevant antigens. J Immunol 2006;177:1729–36.

22. Giles I, Lambrianides N, Latchman D, Chen P, Chukwuocha R, Isenberg D, et al. The critical role of arginine residues in the binding of human antiphospholipid antibodies to cardiolipin. Arthritis Res Ther 2005;7:R47–56.

23. Giles I, Hales J, Nagl S, Latchman D, Chen P, Chukwuocha R, et al. Relative importance of different human aPL derived heavy and light chains in the binding of aPL to cardiolipin. Mol Immunol 2003;40:49–60.

24. Zhu M, Olice T, Le DT, Rouhey RA, Hahn BH, Woods VL Jr, et al. Characterization of IgG monoclonal anti-cardiolipin/anti-B2GPI antibodies from two patients with antiphospholipid syndrome reveals three species of antibodies. Br J Haematol 1999;105:102–9.

25. Pierangeli SS, Liu X, Espinola R, Olice T, Zhu M, Harris NE, et al. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb Haemost 2000;84:388–95.

26. Mason LJ, Lambrianides A, Haley JD, Manson JJ, Latchman DS, Isenberg DA, et al. Stable expression of a recombinant human antinucleosome antibody to investigate relationships between antibody sequence, binding properties, and pathogenicity. Arthritis Res Ther 2005;7:R971–83.

27. Rahman MA, Kettleborough CA, Latchman DS, Isenberg DA. Properties of whole human IgG molecules produced by the expression of cloned anti-DNA antibody cDNA in mammalian cells. J Autoimmun 1998;11:661–9.

28. Ehrenstein MR, Longhurst CM, Latchman DS, Isenberg DA. Serological and genetic characterization of a human monoclonal immunoglobulin G anti-DNA idiotype. J Clin Invest 1994;93:1787–97.

29. Menon S, Rahman MA, Ravirajan CT, Kandiah D, Longhurst CM, McNally T, et al. The production, binding characteristics and sequence analysis of four human IgG monoclonal antiphospholipid antibodies. J Autoimmun 1997;10:43–57.

30. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.

31. Cervera R, Piette JC, Font J, Khamash MA, Shoenfeld Y, Camps MT, et al, for the Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019–27.

32. Vianna JL, Khamash MA, Ordi-Ros J, Font J, Cervera R, Lopez-Soto A, et al. Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med 1994;96:3–9.

33. Bidot CJ, Jy W, Horstman LL, Huisheng H, Jimenez JJ, Yaniz M, et al. Factor VI/VIIa: a new antigen in the antiphospholipid antibody syndrome. Br J Haematol 2003;120:618–26.

34. Jones DW, Gallimore MJ, Mackie IE, Harris SL, Winter M. Reduced factor XII levels in patients with the antiphospholipid syndrome are associated with antibodies to factor XII. Br J Haematol 2000;110:721–6.

35. Cucnik S, Kveder T, Krizaj I, Rozman B, Bozic B. High avidity anti-B2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Ann Rheum Dis 2004;63:1478–82.

36. Bock PE, Olson ST, Bjork I. Inactivation of thrombin by antithrombin is accompanied by inactivation of regulatory exosite I. J Biol Chem 1997;272:19837–45.

37. Miesbach W, Matthias T, Scharrer I. Identification of thrombin antibodies in patients with antiphospholipid syndrome. Ann N Y Acad Sci 2005;1050:250–6.

38. Rahgozar S, Yang Q, Giannakopoulos B, Yan X, Miyakis S, Krilis SA. Beta2-glycoprotein I binds thrombin via exosite I and exosite II: anti-beta2-glycoprotein I antibodies potentiate the inhibitory effect of beta2-glycoprotein I on thrombin-mediated factor Xa generation. Arthritis Rheum 2007;56:605–13.

39. Rahgozar S, Giannakopoulos B, Yan X, Wei J, Cheng Qi JC, Gemmell R, et al. Beta2-glycoprotein I protects thrombin from inhibition by heparin cofactor II: potentiation of this effect in the presence of anti-beta2-glycoprotein I autoantibodies. Arthritis Rheum 2008;58:1146–55.

Errata

In Table 4 of the article by Terekeltaub et al in the August 2011 issue of Arthritis & Rheumatism (pages 2226–237), the colchicine dosing recommendation for acute gout flare with concomitant clarithromycin, ketoconazole, rifampin (strong CYP34A inhibitor) therapy was incorrectly stated. The dosing recommendation should have read “0.6 mg (1 tablet), 1 dose; followed by 0.3 mg (one-half tablet) 1 hour later; dose to be repeated no earlier than 3 days.”

In the article by Tan et al in the September 2011 issue of Arthritis & Rheumatism (pages 2755–2763), the name of an author was omitted: Graciela S. Alarcón, MD, MPH (University of Alabama at Birmingham) should have been listed as an author. Dr. Alarcón participated in acquisition of data for the study, was involved in drafting the article or revising it critically for important intellectual content, and approved the final version to be published.

We regret the errors.

DOI 10.1002/art.33392